products

pipeline

adjuvants
  technology transfer

vaccines

  ghvci

  tb vaccine

  leishmaniasis vaccine

  leprosy vaccine

diagnostics

  leishmaniasis diagnostics

  leprosy diagnostics

  chagas diagnostics

drugs

  tb drug discovery

  lilly tb drug
  discovery initiative


      about us

      working with us

      approach to IP

      faq

      resources
Lilly TB Drug Discovery Initiative

About us

The Lilly TB Drug Discovery Initiative (LTI) is a non-profit public-private partnership with a mission to accelerate early-stage drug discovery and to develop clinical candidates by bringing together specialists from around the world for the systematic exploration of vast, private molecular libraries in search of new TB treatments. Headquartered in Seattle, Washington, the Initiative’s goal is to fill the pipeline with new TB drugs.

Founding Members

Eli Lilly and Company
Infectious Disease Research Institute
National Institute for Allergy and Infectious Disease

Initiative Participants

Jubilant Chemsys Limited
RTI International (RTI)
YourEncore
Academia Sinica


1616 Eastlake Avenue East, Suite 400, Seattle, Washington 98102 office@idri.org  |  P: (206) 381-0883  |  F: (206) 381-3678 © 1993-2016 Privacy Policy
Infectious Disease Research Institute